Targeting GSK ‐3β for adipose dysfunction and cardiovascular complications of metabolic disease: An entangled WNT /β‐catenin question
- 27 December 2024
- journal article
- review article
- Published by Wiley in The FASEB Journal
- Vol. 38 (24) , e70273
Abstract
Individuals with metabolic syndrome have a high risk of developing cardiovascular disorders that is closely tied to visceral adipose tissue dysfunction, as well as an altered interaction between adipose tissue and the cardiovascular system. In metabolic syndrome, adipose tissue dysfunction is associated with increased hypertrophy, reduced vascularization, and hypoxia of adipocytes, leading to a pro‐oxidative and pro‐inflammatory environment. Among the pathways regulating adipose tissue homeostasis is the wingless‐type mammary tumor virus integration site family (Wnt) signaling pathway, with both its canonical and non‐canonical arms. Various modulators of the Wnt signaling have been identified to contribute to the development of metabolic diseases and their cardiovascular complications, with a particularly significant role played by Glycogen Synthase Kinase‐3β (GSK‐3β). GSK‐3β levels and activities have various and often contrasting roles in obesity and related metabolic disorders, as well as their cardiovascular sequelae. Here, we explore the possibility that altered Wnt signaling and GSK‐3β activities could serve as a connection between adipose tissue dysfunction and the development of cardiovascular disease in individuals with metabolic syndrome. We attempt to define a context‐specific approach for intervention, which could possibly serve as a novel disease modifying therapy for the mitigation of such complications.Keywords
Funding Information
- Deanship of Scientific Research, Imam Mohammed Ibn Saud Islamic University (221413005)
This publication has 173 references indexed in Scilit:
- Depot-Biased ROS: A Middleman in Adipose-Driven Cardiovascular Disease2024
- Human RSPO1 Mutation Represses Beige Adipocyte Thermogenesis and Contributes to Diet‐Induced AdiposityAdvanced Science, 2023
- Glycogen synthesis and beyond, a comprehensive review of GSK3 as a key regulator of metabolic pathways and a therapeutic target for treating metabolic diseasesMedicinal Research Reviews, 2021
- The broad pathogenetic role of TCF7L2 in human diseases beyond type 2 diabetesJournal of Cellular Physiology, 2021
- Role of Wnt signaling pathways in type 2 diabetes mellitusMolecular and Cellular Biochemistry, 2021
- Switch from Canonical to Noncanonical Wnt Signaling Mediates High Glucose-Induced AdipogenesisStem Cells, 2014
- Activator or inhibitor? GSK-3 as a new drug targetBiochemical Pharmacology, 2013
- Wnt5b stimulates adipogenesis by activating PPARγ, and inhibiting the β-catenin dependent Wnt signaling pathway together with Wnt5aBiochemical and Biophysical Research Communications, 2009
- WNT10B mutations in human obesityDiabetologia, 2006
- Multisite phosphorylation of glycogen synthaseBiochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology, 1984